Your browser doesn't support javascript.
Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies.
Svacina, Martin K R; Meißner, Anika; Schweitzer, Finja; Ladwig, Anne; Sprenger-Svacina, Alina; Klein, Ines; Wüstenberg, Hauke; Kohle, Felix; Schneider, Christian; Grether, Nicolai B; Wunderlich, Gilbert; Fink, Gereon R; Klein, Florian; Di Cristanziano, Veronica; Lehmann, Helmar C.
  • Svacina MKR; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Meißner A; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Schweitzer F; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Ladwig A; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Sprenger-Svacina A; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Klein I; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Wüstenberg H; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Kohle F; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Schneider C; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Grether NB; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Wunderlich G; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Fink GR; Department of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Klein F; Cognitive Neuroscience, Research Center Jülich, Institute of Neuroscience and Medicine (INM-3), Jülich, Germany.
  • Di Cristanziano V; Institute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Lehmann HC; German Center for Infection Research, partner site Bonn-Cologne, Cologne, Germany.
Eur J Neurol ; 29(11): 3380-3388, 2022 11.
Article in English | MEDLINE | ID: covidwho-1937932
ABSTRACT
BACKGROUND AND

PURPOSE:

This study assessed the prevalence of anti-SARS-CoV-2 antibodies in therapeutic immunoglobulin and their impact on serological response to COVID-19 mRNA vaccine in patients with intravenous immunoglobulin (IVIg)-treated chronic immune neuropathies.

METHODS:

Forty-six samples of different brands or lots of IVIg or subcutaneous IgG were analyzed for anti-SARS-CoV-2 IgG using enzyme-linked immunosorbent assay and chemiluminescent microparticle immunoassay. Blood sera from 16 patients with immune neuropathies were prospectively analyzed for anti-SARS-CoV-2 IgA, IgG, and IgM before and 1 week after IVIg infusion subsequent to consecutive COVID-19 mRNA vaccine doses and after 12 weeks. These were compared to 42 healthy subjects.

RESULTS:

Twenty-four (52%) therapeutic immunoglobulin samples contained anti-SARS-CoV-2 IgG. All patients with immune neuropathies (mean age = 65 ± 16 years, 25% female) were positive for anti-SARS-CoV-2 IgG after COVID-19 vaccination. Anti-SARS-CoV-2 IgA titers significantly decreased 12-14 weeks after vaccination (p = 0.02), whereas IgG titers remained stable (p = 0.2). IVIg did not significantly reduce intraindividual anti-SARS-CoV-2 IgA/IgG serum titers in immune neuropathies (p = 0.69). IVIg-derived anti-SARS-CoV-2 IgG did not alter serum anti-SARS-CoV-2 IgG decrease after IVIg administration (p = 0.67).

CONCLUSIONS:

Our study indicates that IVIg does not impair the antibody response to COVID-19 mRNA vaccine in a short-term observation, when administered a minimum of 2 weeks after each vaccine dose. The infusion of current IVIg preparations that contain anti-SARS-CoV-2 IgG does not significantly alter serum anti-SARS-CoV-2 IgG titers.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Eur J Neurol Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: Ene.15508

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Eur J Neurol Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: Ene.15508